



Functionalized Cyclophellitols Are Selective Glucocerebrosidase Inhibitors and Induce a Bona Fide Neuropathic Gaucher Model in Zebrafish

Marta Artola,^{†,||} Chi-Lin Kuo,^{‡,||} Lindsey T. Lelieveld,[‡] Rhianna J. Rowland,[§] Gijsbert A. van der Marel,[†] Jeroen D. C. Codée,[†] Rolf G. Boot,[‡] Gideon J. Davies,[§] Johannes M. F. G. Aerts,^{*,‡} and Herman S. Overkleeft^{*,†}

[†]Department of Bioorganic Synthesis and [‡]Department of Medical Biochemistry, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands

[§]Department of Chemistry, York Structural Biology Laboratory, University of York, Heslington, York YO10 5DD, United Kingdom

Supporting Information

ABSTRACT: Gaucher disease is caused by inherited deficiency in glucocerebrosidase (GBA, a retaining β -glucosidase), and deficiency in GBA constitutes the largest known genetic risk factor for Parkinson's disease. In the past, animal models of Gaucher disease have been generated by treatment with the mechanism-based GBA inhibitors, conduritol B epoxide (CBE), and cyclophellitols. Both compounds, however, also target other retaining glycosidases, rendering generation and interpretation of such chemical knockout models complicated. Here we demonstrate that cyclophellitols carrying a bulky hydrophobic substituent at C8 are potent and selective GBA inhibitors and that an unambiguous Gaucher animal model can be readily generated by treatment of zebrafish with these.

Glucocerebrosidase (acid glucosylceramidase, GBA, EC 3.2.1.45) is a lysosomal retaining β -glucosidase that belongs to the glycoside hydrolase (GH) 30 family (www.cazy.org)¹ and degrades the glycosphingolipid, glucosylceramide, through a two-step Koshland double displacement mechanism (Figure 1a). Inherited deficiency in GBA causes the most common autosomal recessive lysosomal storage disorder, Gaucher disease.² Individuals carrying heterozygous mutations in the gene coding for GBA do not develop Gaucher disease but have a remarkable increased risk for developing Parkinson's disease (PD) and Lewy-body dementia.^{3–5} Appropriate animal models linking impaired GBA functioning to Gaucher disease and Parkinson's disease are imperative both for understanding the pathophysiology of these diseases and for the development of effective treatments for these. Because complete genetic abrogation of GBA hampers animal viability due to skin permeability problems,⁶ research models have been generated in the past in a chemical knockdown strategy by making use of the mechanism-based, covalent, and irreversible retaining β -glucosidase inhibitor, conduritol B epoxide (CBE, 1, Figure 1b), or its close structural analogue, cyclophellitols (2, Figure 1b).^{7,8} One complication in the use of these compounds is their relative lack of selectivity.⁹ We found that cyclophellitols are unsuited for creating a reliable Gaucher animal model

because it targets GBA and GBA2 with about equal efficiency.⁹ On the other hand, CBE 1 exhibits some GBA selectivity but it also inhibits lysosomal α -glucosidase (GAA),^{10–13} non-lysosomal glucosylceramidase (GBA2),^{14,15} and lysosomal β -glucuronidase (GUSB).¹⁶ Effective mouse models can be generated with CBE 1, but the therapeutic window is rather narrow and varies in cellular and animal models.

Recent research from our group has revealed that functionalized cyclophellitols carrying a BODIPY substituent at C8 (cyclophellitols numbering, the primary carbon corresponding to C6 in glucose) are very potent and very selective activity-based probes (ABPs) for monitoring GBA activity in vitro, in situ, and in vivo.^{17,18} The presence of a bulky and hydrophobic substituent at this position at once proved beneficial for GBA inactivation (ABPs 3 and 4, Figure 1c,d) proved to inhibit GBA in the nanomolar range, whereas cyclophellitols 2 is a high nanomolar to micromolar GBA inactivator) and detrimental to inhibition of other retaining β -glucosidases. Following these studies, Vocadlo and co-workers designed a set of fluorogenic substrates featuring a fluorophore at C6 of a β -glucoside, the aglycon of which carried a fluorescence quencher, compounds that proved to be very selective GBA substrates in situ.¹⁹ These results altogether evoked the question whether cyclophellitols bearing a simple, hydrophobic moiety at C8, such as compounds 6 and 7 (Figure 1d), would be suitable compounds for generating chemical knockdown Gaucher animal models. We show here the validity of this reasoning in the generation of a GBA-deficient *Dario rerio* zebrafish model, as revealed by the accumulation of elevated levels of the Gaucher harbinger lysolipid, glucosylsphingosine, using cyclophellitols derivatives 6 and 7.

At the onset of our studies, we sought for structural support for the design of compounds 6 and 7. We have in the recent past synthesized Cy5-functionalized cyclophellitols 5 (unpublished) and obtained a crystal structure of human recombinant GBA soaked with this ABP (reported here). As expected (Figure 2a), the active site nucleophile (in both molecules of

Received: January 3, 2019

Published: February 27, 2019




Figure 1. (a) Glucocerebrosidase (GBA) hydrolyses glucosylceramide in a two-step double displacement mechanism to yield glucose and ceramide. (b) Chemical structure of CBE **1** and cyclophellitol **2**. (c) Mechanism-based inactivation of GBA by glucopyranoside-configured cyclitol epoxides (shown for cyclophellitol). (d) Structures of C8-extended cyclophellitol derivatives used in the here-presented studies: GBA activity-based probes ABPs **3–5** and selective inhibitors **6** and **7** (see the full chemical structures of ABPs **3–5** and **8–14** in the [Supporting Information \(SI\)](#)).




Figure 2. Structure of GBA reacted with ABP **5** and adamantyl-cyclophellitol **7**. (a) GBA dimer, with the cyclophellitol and linker moiety of **5** shaded in yellow and a single observed Cy5 in pink. (b) Zoomed view of a GBA monomer reacted with ABP **5**. (c) Structure of GBA with adamantyl-cyclophellitol **7**. The linker-adamantyl moiety of **7** is observed in slightly different positions in the two molecules of the asymmetric unit (PDB 6Q6L, [SI, Figure S2](#)), reflecting its binding through predominantly hydrophobic interactions.

the asymmetric unit) had reacted with the epoxide to yield the covalently bound cyclitol in 4C_1 conformation, with the Cy5 moiety, via its flexible linker, clearly bound in one molecule of the asymmetric unit (the differences may reflect crystal packing constraints in a soaking experiment) accommodated by a hydrophobic pocket in GBA. Previous studies by us on the bacterial glycoside hydrolase, *Thermoanaerobacterium xylanolyticum* TxGH116 β -glucosidase, a close homologue of human GBA2 with a conserved active site, instead showed an

“inwards” position of O6 ([SI, Figure 2a](#)) and a narrower and less hydrophobic pocket ([SI, Figure 2b](#)), which may partially mitigate against the binding of O6-functionalised probes, thus allowing sufficient discrimination for GBA over GBA2.^{20,21}

Biphenyl-cyclophellitol **6** and adamantyl-cyclophellitol **7** were synthesized following adaptations of literature cyclophellitol syntheses (see [SI](#) for synthesis details of Cy5-cyclophellitol ABP **5** and compounds **6** and **7**) to generate superior selective GBA inhibitors for the generation of a Gaucher model zebrafish.^{22,23}

Although soaking of GBA crystals with **6** did not yield suitable structures for structural analysis ([SI, Figure S2](#)), soaking with **7** did ([Figure 2c](#)) and again revealed binding of the hydrophobic moiety (here, the adamantane) to the same hydrophobic cavity and pocket occupied by the O6 linker on Cy5 ABP **5**. Several hydrophobic residues, including Tyr313, Phe246, and Trp348 provide the wide cavity that is able to accommodate different hydrophobic O6 substituents which is absent in other human β -glucosidases and which provides the structural basis for the inhibitory (and substrate) preferences of GBA.

We evaluated the *in vitro* activity and selectivity of compounds **6** and **7** toward GBA and the two major off-target glycosidases of CBE **1**, GBA2 and GAA, by preincubating the inhibitors with recombinant human GBA (rGBA, Cerezyme), human GBA2 (from lysates of GBA2 overexpressed cells), and recombinant human GAA (rGAA, Myozyme) for 3 h, followed by enzymatic activity measurement. We showed that both compound **6** and **7** were nanomolar inhibitors of rGBA (apparent IC_{50} values = 1.0 nM), which were 4000-fold more potent than CBE **1** (apparent IC_{50} values = 4.28 μ M) ([Figure 3a, SI, Figure S3](#)) with improved lipophilic ligand efficiencies (LipE) ([SI, Table S2](#)). Both compounds **6** and **7** were rather inactive toward GBA2 and GAA (apparent IC_{50} values >100 μ M), similar to ABP **3** and **5** ([Figure 3a, SI, Figure S4](#)). When comparing their selectivity toward GBA, both compounds **6** and **7** exhibited IC_{50} ratio (GBA2/GBA and GAA/GBA) of >100000, thus making them 4000 times and 200 times more

a	CBE 1 (nM)	CP 2 (nM)	ABP 3 (nM)	ABP 5 (nM)	6 (nM)	7 (nM)
In vitro						
rGBA	4,280 ± 500 ^a	29.6 ± 2.40 ^a	1.20 ± 0.30	3.20 ± 0.17	1.06 ± 0.19	0.96 ± 0.17
GBA2 (HEK293T lysates)	101,000 ± 20,100	29.7 ± 3.13	> 10 ⁵	412,000 ± 10,100	> 10 ⁵	> 10 ⁵
rGAA	1,900,000 ± 192,000	> 10 ⁵	> 10 ⁵	> 10 ⁵	> 10 ⁵	> 10 ⁵
Ratio (in vitro)						
GBA2/ GBA	24	1	> 10 ⁵	> 10 ⁴	> 10 ⁵	> 10 ⁵
GAA/ GBA	444	> 10 ⁵	> 10 ⁵	> 10 ⁵	> 10 ⁵	> 10 ⁵
b	CBE 1 (nM)	CP 2 (nM)	ABP 3 (nM)	ABP 5 (nM)	6 (nM)	7 (nM)
In vivo (Danio rerio larvae)						
GBA	4.41 × 10 ⁴ ^a	83 ^a	31.6 ± 8.88	284 ± 31.5	5.85 ± 2.44	3.94 ± 1.21
GBA2	8.90 × 10 ⁵ ^a	59 ^a	> 10 ⁴	> 10 ⁴	> 10 ⁴	> 10 ⁴
GAA	9.55 × 10 ⁵ ^a	> 10 ⁵ ^a	> 10 ⁴	> 10 ⁴	> 10 ⁴	> 10 ⁴
Ratio (in vivo)						
GBA2/ GBA	22	0.714	> 316	> 35	> 1710	> 2540
GAA/ GBA	233	> 120	> 316	> 35	> 1710	> 2540

^a Values from ref. 9




Figure 3. (a) Apparent IC_{50} values for in vitro inhibition of GBA, GBA2, and GAA in recombinant enzymes (rGBA and rGAA) or overexpressed cell lysates (GBA2) by compounds 1, 2, 3, 5, 6, and 7. Error ranges depict standard deviations from biological triplicates. (b) Apparent IC_{50} values for in vivo inhibition in 5-day treated zebrafish embryo with compounds 1, 2, 3, 5, 6, and 7. Error ranges depict standard deviations from $n = 12$ –24 individuals. (c) Competitive ABPP in lysates of zebrafish treated in vivo with compounds 6 and 7 using broad-spectrum retaining β -glucosidase ABP 8 and selective GBA ABP 5 as readout. (d) Glucosylsphingosine levels produced in zebrafish embryos treated for 5 days with inhibitors 6, 7 or CBE 1.⁹ Error ranges depict standard deviations from $n = 3$ individuals. N/A, not analyzed; *, $p < 0.5$; ***, $p < 0.001$.




Figure 4. In vivo targets of ABP 3 and 7 in brains of adult zebrafish. Competitive ABPP in adult zebrafish homogenates with selective GBA ABP 5 (a) or broad-spectrum retaining β -glucosidase ABP 8 (b) as read-out.

selective than CBE 1 (IC_{50} ratio = 23.6 for GBA2/GBA and 444 for GAA/GBA) (Figure 3a). To evaluate the in vivo activity of compound 6 and 7, compounds were added to the egg–water containing zebrafish (*Danio rerio*) embryos and incubated for 5 days at 28 °C before subsequent homogenization and enzyme selectivity analysis by appropriate ABP labeling.^{9,24} Quantification of ABP-labeled bands revealed that compounds 6 and 7 had in vivo apparent IC_{50} values toward GBA of 4–6 nM, and that they were 5–70-fold more potent than ABP 3 or 5 and 7500-fold more potent than CBE 1 (Figure 3b, SI, Figure S5) in the zebrafish larvae. More importantly, an improved selective inactivation of GBA was achieved with both compounds 6 and 7. At a concentration of 0.1–10 μ M of compound 6 or 7, ABP labeling of GBA with broad-spectrum retaining β -glucosidase ABP 8 (SI, Figure S1) and GBA specific ABP 5 was abrogated (Figure 3c), while other enzymes such as GBA2, LPH (Figure 3c), or GAA, ER α -glucosidase GANAB, and lysosomal β -glucuronidase GUSB (SI, Figure S6a, S6b) were not affected.

At 0.1–10 μ M of inhibitor 6 or 7, we also observed 10–30-fold elevation in the level of glucosylsphingosine (GlcSph), which is known to be formed by acid ceramidase-mediated conversion of accumulating GlcCer in lysosomes.^{25,26} Therefore, this observation also strongly points to in vivo inactivation of lysosomal GBA. For comparison, reaching similar GlcSph levels in the zebrafish with CBE required 1000–10000-fold higher concentration in contrast with compounds 6 or 7 (Figure 3d), concentrations at which GBA2 and GAA may also be targeted (Figure 3b). Finally, we investigated the brain permeability of these new inhibitors, a crucial feature for their future application in the study of neuropathic Gaucher disease and Parkinson's disease. Adult zebrafish of 3 months' age were treated with DMSO, ABP 3, or compound 7 (1.6 nmol/fish, approximately 4 μ mol/kg) administered via food intake, and after 16 h brains and other organs were isolated, homogenized, and analyzed by ABP labeling using ABP 5 (GBA), ABP 8 (GBA2 + GBA), ABP 11 (GAA at pH 4.0 and ER α -glucosidase GANAB at pH 7.0),

and ABP 13 (lysosomal β -glucuronidase GUSB) (SI, Figure S1). Labeling of brain homogenate of adult zebrafish with ABP 5 resulted in considerable GBA labeling in control and ABP 3-treated fish, but no labeling in brain homogenates from fish treated with compound 7 (Figure 4). Labeling by the broad-spectrum β -glucosidase ABP 8 showed that GBA2 was not a target of compound 7, nor was the lower running band (48 kDa), which we hypothesize to be the cytosolic β -glucosidase, GBA3. We noted that the expression level of this protein is likely variable among individual fish, as 4 out of 6 fishes in the control group lacked this band. In the visceral organs (both liver and spleen), both ABP 3 and compound 7 selectively abrogated GBA while not affecting the labeling on other tested glycosidases (SI, Figure S7).

To summarize, crystallographic studies aided the rational design of novel cyclophellitol analogues 6 and 7, which turned out to be very potent and selective GBA inhibitors, also in zebrafish embryos and adult zebrafish (GBA2/GBA inhibition ratio >1000). Compound 7, which also completely block GBA activity in the brain, is in our opinion superior to CBE 1 and CP 2 for generating GBA deficiency on demand in zebrafish, thus to create zebrafish models for neuropathic Gaucher, to assist research in the context of neuropathic GD and PD.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/jacs.9b00056.

Experimental data and procedures, crystallographic data, and synthesis (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

*h.s.overkleeft@lic.leidenuniv.nl

*j.m.f.g.aerts@lic.leidenuniv.nl

ORCID

Marta Artola: 0000-0002-3051-3902

Chi-Lin Kuo: 0000-0003-3748-5008

Jeroen D. C. Codée: 0000-0003-3531-2138

Gideon J. Davies: 0000-0002-7343-776X

Herman S. Overkleeft: 0000-0001-6976-7005

Author Contributions

^{||}M.A. and C.-L.K. contributed equally to this paper.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We thank The Netherlands Organization for Scientific Research (NWO–CW, ChemThem grant to J.M.F.G.A. and H.S.O.), the European Research Council (ERC-2011-AdG-290836 “Chembiosphing” to H.S.O., and ERC-2012-AdG-322942 “Glycopoise” to G.J.D.), Sanofi Genzyme (research grant to J.M.F.G.A. and H.S.O. for financial support and postdoctoral contract to M.A.). R.J.R. is supported by the BBSRC (BB/M011151/1). We thank the Diamond Light Source for access to beamline i02 and i04 (proposal no. mx-13587). G.J.D. is supported by the Royal Society through the Ken Murray Research Professorship.

■ REFERENCES

- (1) Lombard, V.; Golaconda Ramulu, H.; Drula, E.; Coutinho, P. M.; Henrissat, B. The Carbohydrate-Active Enzymes Database (CAZY) in 2013. *Nucleic Acids Res.* **2014**, *42* (D1), D490–D495.
- (2) Brady, R. O.; Kanfer, J. N.; Bradley, R. M.; Shapiro, D. Demonstration of a Deficiency of Glucocerebroside-Cleaving Enzyme in Gaucher's Disease. *J. Clin. Invest.* **1966**, *45*, 1112–1115.
- (3) Schapira, A. H. V. Glucocerebroside and Parkinson Disease: Recent Advances. *Mol. Cell. Neurosci.* **2015**, *66*, 37–42.
- (4) Tsuang, D.; Leverenz, J. B.; Lopez, O. L.; Hamilton, R. L.; Bennett, D. A.; Schneider, J. A.; Buchman, A. S.; Larson, E. B.; Crane, P. K.; Kaye, J. A.; Kramer, P.; Woltjer, R.; Kukull, W.; Nelson, P. T.; Jicha, G. A.; Neltner, J. H.; Galasko, D.; Masliah, E.; Trojanowski, J. Q.; Schellenberg, G. D.; Yearout, D.; Huston, H.; Fritts-Penniman, A.; Mata, I. F.; Wan, J. Y.; Edwards, K. L.; Montine, T. J.; Zabetian, C. P. GBA Mutations Increase Risk for Lewy Body Disease with and without Alzheimer Disease Pathology. *Neurology* **2012**, *79* (19), 1944–1950.
- (5) Sidransky, E.; Nalls, M. A.; Aasly, J. O.; Aharon-Peretz, J.; Annesi, G.; Barbosa, E. R.; Bar-Shira, A.; Berg, D.; Bras, J.; Brice, A.; Chen, C.-M.; Clark, L. N.; Condroyer, C.; De Marco, E. V.; Dürr, A.; Eblan, M. J.; Fahn, S.; Farrer, M. J.; Fung, H.-C.; Gan-Or, Z.; Gasser, T.; Gershoni-Baruch, R.; Giladi, N.; Griffith, A.; Gurevich, T.; Januario, C.; Kropp, P.; Lang, A. E.; Lee-Chen, G.-J.; Lesage, S.; Marder, K.; Mata, I. F.; Mirelman, A.; Mitsui, J.; Mizuta, I.; Nicoletti, G.; Oliveira, C.; Ottman, R.; Orr-Urtreger, A.; Pereira, L. V.; Quattrone, A.; Rogava, E.; Rolfs, A.; Rosenbaum, H.; Rozenberg, R.; Samii, A.; Samadpour, T.; Schulte, C.; Sharma, M.; Singleton, A.; Spitz, M.; Tan, E.-K.; Tayebi, N.; Toda, T.; Troiano, A. R.; Tsuji, S.; Wittstock, M.; Wolfsberg, T. G.; Wu, Y.-R.; Zabetian, C. P.; Zhao, Y.; Ziegler, S. G. Multicenter Analysis of Glucocerebroside Mutations in Parkinson's Disease. *N. Engl. J. Med.* **2009**, *361* (17), 1651–1661.
- (6) Holleran, W. M.; Ginns, E. I.; Menon, G. K.; Grundmann, J. U.; Fartasch, M.; McKinney, C. E.; Elias, P. M.; Sidransky, E. Consequences of β -Glucocerebroside Deficiency in Epidermis. Ultrastructure and Permeability Barrier Alterations in Gaucher Disease. *J. Clin. Invest.* **1994**, *93* (4), 1756–1764.
- (7) Farfel-Becker, T.; Vitner, E. B.; Futerman, A. H. Animal Models for Gaucher Disease Research. *Dis. Models & Mech.* **2011**, *4*, 746–752.
- (8) Vardi, A.; Zigdon, H.; Meshcheriakova, A.; Klein, A. D.; Yaacobi, C.; Eilam, R.; Kenwood, B. M.; Rahim, A. A.; Massaro, G.; Merrill, A. H.; Vitner, E. B.; Futerman, A. H. Delineating Pathological Pathways in a Chemically Induced Mouse Model of Gaucher Disease. *J. Pathol.* **2016**, *239*, 496–509.
- (9) Kuo, C.-L.; Kallemeijn, W. W.; Lelieveld, L.; Mirzaian, T. M.; Zoutendijk, I.; Vardi, A.; Futerman, A. H.; Meijer, A. H.; Spink, H. P.; Overkleeft, H. S.; Aerts, J. M. F. G.; Artola, M. *In Vivo* Inactivation of Glycosidases by Conduritol B Epoxide and Cyclophellitol as Revealed by Activity-Based Protein Profiling. *FEBS J.* **2019**, *286* (3), 584–600.
- (10) Quaroni, A.; Gershon, E.; Semenza, G. Affinity Labeling of the Active Sites in the Sucrase-Isomaltase Complex from Small Intestine. *J. Biol. Chem.* **1974**, *249*, 6424–6433.
- (11) Shou-jun, Y.; Su-guo, G.; Yu-cheng, Z.; Shu-zheng, Z. Inactivation of α -Glucosidase by the Active-Site-Directed Inhibitor, Conduritol B Epoxide. *Biochim. Biophys. Acta, Protein Struct. Mol. Enzymol.* **1985**, *828* (3), 236–240.
- (12) Hermans, M. M. P.; Krooss, M. A.; van Beeunens, J.; Oostras, B. A.; Reusersll, A. J. J. Human Lysosomal α -Glucosidase Characterization of the Catalytic Site. *J. Biol. Chem.* **1991**, *266* (21), 13507–13512.
- (13) Braun, H.; Legler, G.; Deshusses, J.; Semenza, G. Stereospecific Ring Opening of Conduritol-B-Epoxide by an Active Site Aspartate Residue of Sucrase-Isomaltase. *BBA - Enzymol.* **1977**, *483* (1), 135–140.
- (14) van Weely, S.; Brandsma, M.; Strijland, A.; Tager, J. M.; Aerts, J. M. F. G. Demonstration of the Existence of a Second, Non-Lysosomal Glucocerebroside That Is Not Deficient in Gaucher

Disease. *Biochim. Biophys. Acta, Mol. Basis Dis.* **1993**, *1181* (1), 55–62.

(15) Ridley, C. M.; Thur, K. E.; Shanahan, J.; Thillaiappan, N. B.; Shen, A.; Uhl, K.; Walden, C. M.; Rahim, A. A.; Waddington, S. N.; Platt, F. M.; Van Der Spoel, A. C. β -Glucosidase 2 (GBA2) Activity and Imino Sugar Pharmacology. *J. Biol. Chem.* **2013**, *288* (36), 26052–26066.

(16) Hara, A.; Radin, N. S. Enzymic Effects of β -Glucosidase Destruction in Mice Changes in Glucuronidase Levels. *Biochim. Biophys. Acta, Gen. Subj.* **1979**, *582* (3), 423–433.

(17) Witte, M. D.; Kallemeijn, W. W.; Aten, J.; Li, K. Y.; Strijland, A.; Donker-Koopman, W. E.; van den Nieuwendijk, A. M. C. H.; Bleijlevens, B.; Kramer, G.; Florea, B. I.; Hooibrink, B.; Hollak, C. E. M.; Ottenhoff, R.; Boot, R. G.; van der Marel, G. A.; Overkleeft, H. S.; Aerts, J. M. F. G. Ultrasensitive in Situ Visualization of Active Glucocerebrosidase Molecules. *Nat. Chem. Biol.* **2010**, *6* (12), 907–913.

(18) Herrera Moro Chao, D.; Kallemeijn, W. W.; Marques, A. R. A.; Orre, M.; Ottenhoff, R.; van Roomen, C.; Foppen, E.; Renner, M. C.; Moeton, M.; van Eijk, M.; Boot, R. G.; Kamphuis, W.; Hol, E. M.; Aten, J.; Overkleeft, H. S.; Kalsbeek, A.; Aerts, J. M. F. G. Visualization of Active Glucocerebrosidase in Rodent Brain with High Spatial Resolution Following in Situ Labeling with Fluorescent Activity Based Probes. *PLoS One* **2015**, *10* (9), No. e0138107.

(19) Yadav, A. K.; Shen, D. L.; Shan, X.; He, X.; Kermode, A. R.; Vocadlo, D. J. Fluorescence-Quenched Substrates for Live Cell Imaging of Human Glucocerebrosidase Activity. *J. Am. Chem. Soc.* **2015**, *137* (3), 1181–1189.

(20) Lahav, D.; Liu, B.; van den Berg, R. J. B. H. N.; van den Nieuwendijk, A. M. C. H.; Wennekes, T.; Ghisaidoobe, A. T.; Breen, I.; Ferraz, M. J.; Kuo, C. L.; Wu, L.; Geurink, P. P.; Ova, H.; van der Marel, G. A.; van der Stelt, M.; Boot, R. G.; Davies, G. J.; Aerts, J. M. F. G.; Overkleeft, H. S. A Fluorescence Polarization Activity-Based Protein Profiling Assay in the Discovery of Potent, Selective Inhibitors for Human Nonlysosomal Glucosylceramidase. *J. Am. Chem. Soc.* **2017**, *139* (40), 14192–14197.

(21) Charoenwattanasatien, R.; Pengthaisong, S.; Breen, I.; Mutoh, R.; Sansenya, S.; Hua, Y.; Tankrathok, A.; Wu, L.; Songsiriritthigul, C.; Tanaka, H.; Williams, S. J.; Davies, G. J.; Kurisu, G.; Cairns, J. R. K. Bacterial β -Glucosidase Reveals the Structural and Functional Basis of Genetic Defects in Human Glucocerebrosidase 2 (GBA2). *ACS Chem. Biol.* **2016**, *11* (7), 1891–1900.

(22) Berger, J.; Lecourt, S.; Vanneaux, V.; Rapatel, C.; Boisgard, S.; Caillaud, C.; Boiret-Dupré, N.; Chomienne, C.; Marolleau, J. P.; Larghero, J.; Berger, M. G. Glucocerebrosidase Deficiency Dramatically Impairs Human Bone Marrow Haematopoiesis in an in Vitro Model of Gaucher Disease. *Br. J. Haematol.* **2010**, *150* (1), 93–101.

(23) Schueler, U. H.; Kolter, T.; Kaneski, C. R.; Zirzow, G. C.; Sandhoff, K.; Brady, R. O. Correlation between Enzyme Activity and Substrate Storage in a Cell Culture Model System for Gaucher Disease. *J. Inherited Metab. Dis.* **2004**, *27* (1), 649–658.

(24) Kuo, C. L.; van Meel, E.; Kytidou, K.; Kallemeijn, W. W.; Witte, M.; Overkleeft, H. S.; Artola, M. E.; Aerts, J. M. Activity-Based Probes for Glycosidases: Profiling and Other Applications. *Methods Enzymol.* **2018**, *598*, 217–235.

(25) Dekker, N.; van Dussen, L.; Hollak, C. E. M.; Overkleeft, H.; Scheij, S.; Ghauharali, K.; van Breemen, M. J.; Ferraz, M. J.; Groener, J. E. M.; Maas, M.; Wijburg, F. A.; Speijer, D.; Tylki-Szymanska, A.; Mistry, P. K.; Boot, R. G.; Aerts, J. M. Elevated Plasma Glucosylsphingosine in Gaucher Disease: Relation to Phenotype, Storage Cell Markers, and Therapeutic Response. *Blood* **2011**, *118* (16), e118–e127.

(26) Ferraz, M. J.; Marques, A. R. A.; Appelman, M. D.; Verhoek, M.; Strijland, A.; Mirzaian, M.; Scheij, S.; Ouairy, C. M.; Lahav, D.; Wisse, P.; Overkleeft, H. S.; Boot, R. G.; Aerts, J. M. Lysosomal Glycosphingolipid Catabolism by Acid Ceramidase: Formation of Glycosphingoid Bases during Deficiency of Glycosidases. *FEBS Lett.* **2016**, *590*, 716–725.